Key Takeaways
Travere Therapeutics Inc. (Nasdaq: TVTX) received full U.S. Food and Drug Administration approval for its drug Filspari to treat focal segmental glomerulosclerosis, expanding the drug’s total addressable U.S. market to over 100,000 patients.
"Today marks a historic milestone for people living with FSGS, who for the first time have an FDA-approved medicine for this rare and devastating condition," Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics, said in a statement.
The approval for the drug, known as sparsentan, is for adults and children aged 8 and older with FSGS who do not have nephrotic syndrome. The company estimates this adds more than 30,000 addressable patients. In the Phase 3 DUPLEX study, these patients saw a statistically significant 48% reduction in proteinuria by week 108, compared to a 27% reduction for patients on the control drug, irbesartan.
Shares of Travere Therapeutics jumped on the news Tuesday. The decision makes Filspari the first and only FDA-approved medicine for FSGS, adding a second indication to its existing approval for IgA nephropathy (IgAN) and significantly increasing its revenue potential.
The approval is based on results from the Phase 3 DUPLEX Study, the largest interventional study in FSGS to date. Beyond the primary endpoint of proteinuria reduction, Filspari-treated patients without nephrotic syndrome also showed a benefit in estimated glomerular filtration rate (eGFR), a key measure of kidney function. The mean change in eGFR from baseline to Week 108 was -11.3 mL/min/1.73 m2 for Filspari, compared to -12.4 mL/min/1.73 m2 for irbesartan.
"For decades, treatment options have been limited, often relying on off-label therapies such as long-term steroids that can carry a significant burden for patients," said Kirk Campbell, M.D., president of the National Kidney Foundation. "In the DUPLEX Study, FILSPARI delivered rapid and sustained reductions in proteinuria... For patients without active nephrotic syndrome, where optimizing foundational therapy is critical, FILSPARI represents an important new option."
The approval solidifies Filspari's position as a foundational treatment for rare kidney diseases. The expanded label to include FSGS, a progressive disorder characterized by kidney scarring, provides a new, targeted therapy for a patient population with high unmet need. The company will make the drug immediately available for physicians to prescribe.
This article is for informational purposes only and does not constitute investment advice.
